141 related articles for article (PubMed ID: 36617959)
1. The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study.
Yamamoto M; Sickle-Santanello B; Beard T; Essner R; Martin B; Bailey CN; Guenther JM
Curr Med Res Opin; 2023 Mar; 39(3):417-423. PubMed ID: 36617959
[TBL] [Abstract][Full Text] [Related]
2. Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary.
Johansson I; Tempel D; Dwarkasing JT; Rentroia-Pacheco B; Mattsson J; Ny L; Olofsson Bagge R
Eur J Surg Oncol; 2022 Feb; 48(2):320-325. PubMed ID: 34794843
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of the clinicopathologic and gene expression profile (CP-GEP) in patients with melanoma eligible for sentinel lymph node biopsy: A multicenter prospective Dutch study.
Stassen RC; Mulder EEAP; Mooyaart AL; Francken AB; van der Hage J; Aarts MJB; van der Veldt AAM; Verhoef C; Grünhagen DJ
Eur J Surg Oncol; 2023 Dec; 49(12):107249. PubMed ID: 37907016
[TBL] [Abstract][Full Text] [Related]
4. Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.
Mulder EEAP; Dwarkasing JT; Tempel D; van der Spek A; Bosman L; Verver D; Mooyaart AL; van der Veldt AAM; Verhoef C; Nijsten TEC; Grunhagen DJ; Hollestein LM
Br J Dermatol; 2021 May; 184(5):944-951. PubMed ID: 32844403
[TBL] [Abstract][Full Text] [Related]
5. Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy.
Kött J; Zimmermann N; Zell T; Rünger A; Heidrich I; Geidel G; Smit DJ; Hansen I; Abeck F; Schadendorf D; Eggermont A; Puig S; Hauschild A; Gebhardt C
Eur J Cancer; 2024 May; 202():113989. PubMed ID: 38518535
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy.
Gerami P; Cook RW; Russell MC; Wilkinson J; Amaria RN; Gonzalez R; Lyle S; Jackson GL; Greisinger AJ; Johnson CE; Oelschlager KM; Stone JF; Maetzold DJ; Ferris LK; Wayne JD; Cooper C; Obregon R; Delman KA; Lawson D
J Am Acad Dermatol; 2015 May; 72(5):780-5.e3. PubMed ID: 25748297
[TBL] [Abstract][Full Text] [Related]
7. Utility of a Model for Predicting the Risk of Sentinel Lymph Node Metastasis in Patients With Cutaneous Melanoma.
Marchetti MA; Dusza SW; Bartlett EK
JAMA Dermatol; 2022 Jun; 158(6):680-683. PubMed ID: 35475908
[TBL] [Abstract][Full Text] [Related]
8. Integration of a 31-Gene Expression Profile Into Clinical Decision-Making in the Treatment of Cutaneous Melanoma.
Scott AM; Dale PS; Conforti A; Gibbs JN
Am Surg; 2020 Nov; 86(11):1561-1564. PubMed ID: 32755379
[TBL] [Abstract][Full Text] [Related]
9. Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis Prediction.
Whitman ED; Koshenkov VP; Gastman BR; Lewis D; Hsueh EC; Pak H; Trezona TP; Davidson RS; McPhee M; Guenther JM; Toomey P; Smith FO; Beitsch PD; Lewis JM; Ward A; Young SE; Shah PK; Quick AP; Martin BJ; Zolochevska O; Covington KR; Monzon FA; Goldberg MS; Cook RW; Fleming MD; Hyams DM; Vetto JT
JCO Precis Oncol; 2021; 5():. PubMed ID: 34568719
[TBL] [Abstract][Full Text] [Related]
10. Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: A U.S. cohort study.
Yousaf A; Tjien-Fooh FJ; Rentroia-Pacheco B; Quattrocchi E; Kobic A; Tempel D; Kolodney M; Meves A
Int J Dermatol; 2021 Jul; 60(7):851-856. PubMed ID: 33914348
[TBL] [Abstract][Full Text] [Related]
11. Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test.
Jarell A; Gastman BR; Dillon LD; Hsueh EC; Podlipnik S; Covington KR; Cook RW; Bailey CN; Quick AP; Martin BJ; Kurley SJ; Goldberg MS; Puig S
J Am Acad Dermatol; 2022 Dec; 87(6):1312-1320. PubMed ID: 35810840
[TBL] [Abstract][Full Text] [Related]
12. The Integrated i31-GEP Test Outperforms the MSKCC Nomogram at Predicting SLN Status in Melanoma Patients.
Tassavor M; Martin BJ; Glazer AM
Anticancer Res; 2023 Oct; 43(10):4511-4516. PubMed ID: 37772588
[TBL] [Abstract][Full Text] [Related]
13. Sentinel lymph node biopsy for melanoma: indications and rationale.
Phan GQ; Messina JL; Sondak VK; Zager JS
Cancer Control; 2009 Jul; 16(3):234-9. PubMed ID: 19556963
[TBL] [Abstract][Full Text] [Related]
14. Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma.
Miller JR; Lo SN; Nosrati M; Stretch JR; Spillane AJ; Saw RPM; Shannon KF; Nieweg OE; Ch'ng S; Kim KB; Leong SP; Thompson JF; Scolyer RA; Kashani-Sabet M
JAMA Netw Open; 2023 Apr; 6(4):e236356. PubMed ID: 37074717
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma.
Gannon CJ; Rousseau DL; Ross MI; Johnson MM; Lee JE; Mansfield PF; Cormier JN; Prieto VG; Gershenwald JE
Cancer; 2006 Dec; 107(11):2647-52. PubMed ID: 17063497
[TBL] [Abstract][Full Text] [Related]
16. Compliance with sentinel lymph node biopsy guidelines for invasive melanomas treated with Mohs micrographic surgery.
MacArthur KM; Baumann BC; Sobanko JF; Etzkorn JR; Shin TM; Higgins HW; Giordano CN; McMurray SL; Krausz A; Newman JG; Rajasekaran K; Cannady SB; Brody RM; Karakousis GC; Miura JT; Cohen JV; Amaravadi RK; Mitchell TC; Schuchter LM; Miller CJ
Cancer; 2021 Oct; 127(19):3591-3598. PubMed ID: 34292585
[TBL] [Abstract][Full Text] [Related]
17. Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma.
Yamamoto M; Fisher KJ; Wong JY; Koscso JM; Konstantinovic MA; Govsyeyev N; Messina JL; Sarnaik AA; Cruse CW; Gonzalez RJ; Sondak VK; Zager JS
Cancer; 2015 May; 121(10):1628-36. PubMed ID: 25677366
[TBL] [Abstract][Full Text] [Related]
18. Cervical sentinel lymph node biopsy for melanomas of the head and neck and upper thorax.
Wagner JD; Park HM; Coleman JJ; Love C; Hayes JT
Arch Otolaryngol Head Neck Surg; 2000 Mar; 126(3):313-21. PubMed ID: 10722003
[TBL] [Abstract][Full Text] [Related]
19. Sentinel lymph node biopsy in cutaneous melanoma: a case-control study.
Koskivuo I; Talve L; Vihinen P; Mäki M; Vahlberg T; Suominen E
Ann Surg Oncol; 2007 Dec; 14(12):3566-74. PubMed ID: 17924169
[TBL] [Abstract][Full Text] [Related]
20. Quality of life after axillary or groin sentinel lymph node biopsy, with or without completion lymph node dissection, in patients with cutaneous melanoma.
de Vries M; Hoekstra HJ; Hoekstra-Weebers JE
Ann Surg Oncol; 2009 Oct; 16(10):2840-7. PubMed ID: 19639366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
